Resource Summary Report

Generated by NIF on Apr 9, 2025

Cancer Cell Line Encyclopedia

RRID:SCR_013836

Type: Tool

Proper Citation

Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Resource Information

URL: https://www.broadinstitute.org/ccle/

Proper Citation: Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Description: A collaborative project between the Broad Institute and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation, with the goal of conducting a detailed genetic and pharmacologic characterization of a large panel of human cancer models. The CCLE also works to develop integrated computational analyses that link distinct pharmacologic vulnerabilities to genomic patterns and to translate cell line integrative genomics into cancer patient stratification. The CCLE provides public access to genomic data, analysis and visualization for about 1000 cell lines.

Abbreviations: CCLE

Resource Type: database, data or information resource, project portal, portal

Defining Citation: DOI:10.1038/nature11003

Keywords: cancer, cell line, human, human cancer model, genetic, portal, database, FASEB

list

Funding:

Availability: Public

Resource Name: Cancer Cell Line Encyclopedia

Resource ID: SCR 013836

Record Creation Time: 20220129T080318+0000

Record Last Update: 20250409T061208+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Cell Line Encyclopedia.

No alerts have been found for Cancer Cell Line Encyclopedia.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 73 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Schott CR, et al. (2024) Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. Clinical cancer research: an official journal of the American Association for Cancer Research, 30(4), 849.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. Cancer research communications, 4(12), 3084.

Taylor B, et al. (2024) Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication. Neuro-oncology advances, 6(1), vdae104.

Sawant NV, et al. (2024) VesiX cetylpyridinium chloride is rapidly bactericidal and reduces uropathogenic Escherichia coli bladder epithelial cell invasion in vitro. Microbiology spectrum, 12(3), e0271223.

Liu W, et al. (2024) Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer. Scientific reports, 14(1), 19025.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clinical cancer research: an official journal of the American Association for Cancer Research, OF1.

Hayes TK, et al. (2024) Comprehensive mutational scanning of EGFR reveals TKI

sensitivities of extracellular domain mutants. Nature communications, 15(1), 2742.

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. Cancer letters, 587, 216702.

Li L, et al. (2023) PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma. Aging, 15(11), 5215.

Wang CZ, et al. (2023) Comprehensive characterization of TGFB1 across hematological malignancies. Scientific reports, 13(1), 19107.

Wang Q, et al. (2023) DEPDC1B-mediated USP5 deubiquitination of ?-catenin promotes breast cancer metastasis by activating the wnt/?-catenin pathway. American journal of physiology. Cell physiology, 325(4), C833.

Turan T, et al. (2023) iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type-Specific Markers of Immune-Cell Infiltration. Cancer immunology research, 11(6), 732.

Zhang B, et al. (2023) An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer. Advances in therapy, 40(10), 4339.

Han W, et al. (2023) Heme Metabolism-Related Gene TENT5C is a Prognostic Marker and Investigating Its Immunological Role in Colon Cancer. Pharmacogenomics and personalized medicine, 16, 1127.

Tomas Bort E, et al. (2023) Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. eLife, 12.

Chen B, et al. (2023) Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer. Scientific reports, 13(1), 16244.

Xu ZJ, et al. (2023) Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. Cancer medicine, 12(1), 789.

Xu X, et al. (2023) Comprehensive bioinformatic analysis of the expression and prognostic significance of TSC22D domain family genes in adult acute myeloid leukemia. BMC medical genomics, 16(1), 117.

Yadav A, et al. (2023) Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer. Cancer research communications, 3(10), 2044.

Vad-Nielsen J, et al. (2023) Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. Translational lung cancer research, 12(1), 42.